News

Published on 31 Jan 2023 on Zacks via Yahoo Finance

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?


Article preview image

Incyte Corporation INCY is scheduled to release its fourth-quarter and full-year 2022 results on Feb 7, before market open.

The company’s earnings surprise history has been dismal so far, with its earnings beating the Zacks Consensus Estimate in only one of the trailing four quarters and missing on the other three occasions, with the average negative surprise being 20.11%. In the last reported quarter, Incyte missed earnings by 16.67%.

Shares of Incyte have risen 12.5% in the past year against the industry’s decline of 10.4%.

NYSE.NVS price evolution
SIX.NOVN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

Novartis NVS presented encouraging results from a pre-specified interim analysis of the phase III...

Zacks via Yahoo Finance 16 Apr 2024

Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly...

There's a common problem with passive income: Generating it isn't as passive as investors expect....

Motley Fool via Yahoo Finance 14 Apr 2024

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis NVS entered into an exclusive strategic license agreement with a clinical-stage biotechn...

Zacks via Yahoo Finance 12 Apr 2024

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact -...

On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences I...

Benzinga 11 Apr 2024

Novartis (NVS) to Undertake Job Cuts in Development Department

Novartis NVS is set to reduce its workforce by 680, per a report by Reuters. It will do so in its...

Zacks via Yahoo Finance 11 Apr 2024

Vertex Pharma’s takeover of Alpine Immune is a strategic fit: analysts

Alpine Immune’s lead candidate is being evaluated as a potential treatment for IgA Nephropathy, o...

Market Watch 11 Apr 2024

Novartis commences tender offer for MorphoSys (NYSE:NVS)

Novartis has commenced its tender offer to acquire MorphoSys for €2.7B, offering a premium of 142...

Seeking Alpha 11 Apr 2024

MorphoSys recommends shareholders to accept Novartis takeover offer

The offer is set at €68.00 per share, totaling an equity value of €2.7 billion. This price reflec...

Investing.com 11 Apr 2024

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover...

The offer price corresponds to a premium of 94% and 142% on the volume-weighted...

Investing.com 11 Apr 2024

Why Is Novartis Stock Trading Higher On Thursday? - Novartis (NYSE:NVS)

Thursday, Novartis AG NVS shares are trading higher after the company confirmed plans to file for...

Benzinga 4 Apr 2024